{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:21:05Z","timestamp":1777926065180,"version":"3.51.4"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To determine vascular age (VA) in a cohort of persons with multiple sclerosis (PwMS) in Belgrade, Serbia, and to assess the difference between chronological age (CA) and VA, in this population.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Material and methods<\/jats:title>\n<jats:p>A case-control study was conducted at the Clinic of Neurology, University Clinical Center of Serbia in Belgrade. Study participants (n = 274) were recruited during regular outpatient visits. Demographic and clinical characteristics including the presence of CVD comorbidities of PwMS were collected. Data were obtained using a questionnaire, designed and adapted for the study purposes. Additionally, fasting blood samples were collected from all participants, in order to determine their lipid profile. VA was calculated based on the patient\u2019s sex, age, smoking status, total serum cholesterol level and systolic blood pressure (SBP) value. Afterwards, the study sample was divided into five groups with the different levels of the atherosclerotic burden, as follows: 1) PwMS without any CVD comorbidity; 2) PwMS with hyperlipidemia (HLP); 3) PwMS with HLP and hypertension (HTA); 4) PwMS with HLP, HTA and type 2 diabetes, and 5) PwMS with coronary artery disease (CAD). In the statistical analysis, for the determination of factors that are independently associated with the discrepancy between CA and VA in persons with MS, hierarchical regression analysis was performed.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>The mean values of CA and VA were statistically significantly different among the groups(p&lt;0.001). Additionally, a significant difference was also detected between CA and VA (p&lt;0.001). The highest VA (66.4\u00b115.8 years) and the difference between CA and VA (6.5\u00b17.3 years) were registered only in the group comprising PwMS, HPL, HTA and type 2 diabetes. Results of the hierarchical linear regression analysis showed that the Expanded Disability Status Scale (EDSS) score, Body mass index (BMI), physical activity and the presence of type 2 diabetes, explained a total of 24% of the variations in the difference between CA and VA, in our cohort of MS patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our study showed significant difference between CA and VA in PwMS and additionally, increasing VA with atherosclerotic burden. Additionally, it has been demonstrated that crucial factors which led to the occurrence of these differences were BMI, physical activity, EDSS and the presence of type 2 diabetes.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0311117","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T18:35:47Z","timestamp":1732127747000},"page":"e0311117","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigation of differences between chronological and vascular age in persons with multiple sclerosis"],"prefix":"10.1371","volume":"19","author":[{"given":"Gorica D.","family":"Maric","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1409","authenticated-orcid":true,"given":"Tatjana D.","family":"Pekmezovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivera S.","family":"Tamas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola D.","family":"Veselinovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja S.","family":"Budimkic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksa L.","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarlota K.","family":"Mesaros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4516-3458","authenticated-orcid":true,"given":"Jelena S.","family":"Drulovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"pone.0311117.ref001","unstructured":"MS International Federation. 3rd edition of the Atlas of MS. Available online at: https:\/\/www.atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-ms#about (Accessed September 11, 2023)."},{"key":"pone.0311117.ref002","doi-asserted-by":"crossref","first-page":"794075","DOI":"10.3389\/fimmu.2021.794075","article-title":"(2022) Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population","volume":"12","author":"HS Ng","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"pone.0311117.ref003","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial","volume":"22","author":"JR Corboy","year":"2023","journal-title":"Lancet Neurol"},{"issue":"16","key":"pone.0311117.ref004","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1212\/WNL.0000000000004508","article-title":"Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality","volume":"89","author":"A Thormann","year":"2017","journal-title":"Neurology"},{"key":"pone.0311117.ref005","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3389\/fneur.2020.00851","article-title":"Comorbidity in multiple sclerosis","volume":"11","author":"M Magyari","year":"2020","journal-title":"Front Neurol"},{"issue":"5","key":"pone.0311117.ref006","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s10072-020-04727-5","article-title":"The prevalence of comorbidities in patients with multiple sclerosis: population-based registry data","volume":"42","author":"GD Maric","year":"2021","journal-title":"Neurol Sci"},{"issue":"3","key":"pone.0311117.ref007","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1212\/WNL.0000000000001718","article-title":"Effect of comorbidity on mortality in multiple sclerosis","volume":"85","author":"RA Marrie","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"pone.0311117.ref008","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/jnnp-2015-310361","article-title":"Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios","volume":"87","author":"A Manouchehrinia","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"pone.0311117.ref009","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ane.13559","article-title":"Standardized mortality ratios in multiple sclerosis: Systematic review with meta-analysis","volume":"145","author":"N Smyrke","year":"2022","journal-title":"Acta Neurol Scand"},{"issue":"13","key":"pone.0311117.ref010","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e3181d6b125","article-title":"Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis","volume":"74","author":"RA Marrie","year":"2010","journal-title":"Neurology"},{"issue":"13","key":"pone.0311117.ref011","first-page":"e1322","article-title":"Interface of multiple sclerosis, depression, vascular disease, and mortality","volume":"97","author":"R Palladino","year":"2021","journal-title":"A Population-Based Matched Cohort Study"},{"issue":"2","key":"pone.0311117.ref012","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/1352458516650512","article-title":"Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course","volume":"23","author":"DS Conway","year":"2017","journal-title":"Mult Scler"},{"key":"pone.0311117.ref013","doi-asserted-by":"crossref","first-page":"102536","DOI":"10.1016\/j.msard.2020.102536","article-title":"Could the performance of oral glucose tolerance test contribute to the brain health-focused care in multiple sclerosis?","volume":"46","author":"G Maric","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"pone.0311117.ref014","article-title":"Subclinical atherosclerosis in multiple sclerosis","volume":"10","author":"RA Marrie","year":"2024","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"19","key":"pone.0311117.ref015","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1093\/eurheartj\/ehq205","article-title":"How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation","volume":"31","author":"JI Cuende","year":"2010","journal-title":"Eur Heart J"},{"key":"pone.0311117.ref016","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"RB D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"pone.0311117.ref017","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"AJ Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"11","key":"pone.0311117.ref018","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"JF Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"2","key":"pone.0311117.ref019","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neurad.2019.10.002","article-title":"Is multiple sclerosis a risk factor for atherosclerosis?","volume":"48","author":"B Yuksel","year":"2021","journal-title":"J Neuroradiol"},{"key":"pone.0311117.ref020","doi-asserted-by":"crossref","first-page":"1197212","DOI":"10.3389\/fneur.2023.1197212","article-title":"Impact of aging on treatment considerations for multiple sclerosis patients","volume":"14","author":"G Macaron","year":"2023","journal-title":"Front Neurol"},{"issue":"5","key":"pone.0311117.ref021","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ahj.2014.06.028","article-title":"Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications","volume":"168","author":"J Camm","year":"2014","journal-title":"Am Heart J"},{"key":"pone.0311117.ref022","doi-asserted-by":"crossref","first-page":"102844","DOI":"10.1016\/j.msard.2021.102844","article-title":"Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program","volume":"51","author":"KW Selmaj","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"14","key":"pone.0311117.ref023","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"P O\u2019Connor","year":"2011","journal-title":"N Engl J Med"},{"issue":"15","key":"pone.0311117.ref024","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.3390\/jcm12154948","article-title":"The Prevalence of Diabetes Mellitus Type II (DMII) in the Multiple Sclerosis Population: A Systematic Review and Meta-Analysis","volume":"12","author":"V Giannopapas","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"pone.0311117.ref025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ane.13516","article-title":"Impact of comorbidities on the disability progression in multiple sclerosis","volume":"145","author":"G Maric","year":"2022","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"pone.0311117.ref026","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3174\/ajnr.A4681","article-title":"Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis","volume":"37","author":"R Zivadinov","year":"2016","journal-title":"AJNR Am J Neuroradiol"},{"issue":"Suppl 1","key":"pone.0311117.ref027","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","article-title":"Brain health: time matters in multiple sclerosis","volume":"9","author":"G Giovannoni","year":"2016","journal-title":"Mult Scler Relat Disord"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T18:35:54Z","timestamp":1732127754000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0311117"}},"subtitle":[],"editor":[{"given":"Orhan","family":"Aktas","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0311117","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]}}}